Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Trial end date:
2020-12-07
Target enrollment:
Participant gender:
Summary
This study will test to see if metformin is safe and if it is tolerated compared to placebo
in adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with beginning stages
of chronic kidney disease. We will also measure its effect on progression of kidney disease
as reflected in the kidney size and the kidney function, along with its effect on kidney pain
and quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
Kyongtae Ty Bae, M.D., Ph.D. University of Pittsburgh
Collaborators:
Tufts Medical Center United States Department of Defense University of Maryland University of Maryland, Baltimore University of Southern California